Why the study?
Hematopoietic stem cell transplantation is known to cause cardiac toxicity, but the impact of the mobilization procedure on left and right ventricle sizes and functions was unclear.
Does hematopoietic stem cell mobilization with chemotherapy and filgrastim affect ventricular size and function in patients undergoing autologous HSCT?
Does hematopoietic stem cell mobilization with chemotherapy and filgrastim affect ventricular size and function in patients undergoing autologous HSCT?
The mobilization procedure for autologous HSCT is associated with an early, significant reduction in right ventricular systolic function as measured by S'.
HSCT mobilization effects on ventricular function remain uncertain in small cohorts; larger prospective studies needed before clinical adoption.
Background: The hematopoietic stem cell transplantation (HSCT) process is known to cause cardiac toxicity of different grades. In this paper, we aimed to evaluate the impact of mobilization procedure of hematopoietic stem cells for autologous HSCT process for left and right ventricle sizes and functions. Material and Methods: The data of 47 patients undergoing autologous HSCT were analyzed. All patients underwent hematopoietic stem cell mobilization with chemotherapy and filgrastim at 10 µg/kg/d. Echocardiography was performed two times: before enrolling in the transplantation process and after mobilization before the conditioning regimen for transplantation. Changes in left and right ventricle (RV) diameter and systolic and diastolic function of the left ventricle and systolic function of the RV were measured. Results: A statistically significant difference was observed in the change of right ventricular function (S‘)—it slightly decreased. Mean S‘ before mobilization was 13.93 ± 2.85 cm/s, and after mobilization it was 12.19 ± 2.64 cm/s (p = 0.003). No statistically significant change in left ventricular diameter and systolic and diastolic function and RV diameter was observed. Conclusions: The mobilization procedure in patients undergoing autologous HSCT is associated with reduced RV systolic function. S‘ could be used as a reliable tool to evaluate early cardiotoxicity in HSCT patients and guide further follow-up.
No takes yet. Share an insight, caveat, or question.
Vaitiekienė et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: